92809-96-6Relevant articles and documents
BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS
-
Page/Page column 31-32, (2008/06/13)
The present invention provides compounds having formula (I) wherein n, p, q and r are each independently selected from 0 or 1; a, b, c, and d each independently represents a carbon or nitrogen atom, with the proviso that no more than two of a, b, c, and d are nitrogen atoms; Y and Y' each independently represents 1-4 optional substituents selected from alkyl, alkoxy, halo, -CF3, and -C(O)OH; R, R, R and R are H or specified substituents; R, R, R, R, R, R, R and R are independently selected from H or C1-C3 alkyl; or a biolabile ester thereof, or a pharmaceutically acceptable salt thereof. Also provided are methods of using these compounds for treating vitronectin-mediated disorders, e.g., cancer, retinopathy, artherosclerosis, vascular restenosis, and osteoporosis.
Integrin receptor antagonists
-
, (2008/06/13)
Compounds of formula (I) STR1 wherein A1 is C or N; E is a five- or six-membered heteroaromatic or six-membered aromatic ring optionally substituted by R3 or R4 ; X1 --X2 is CHR1 --CH, CR1 =CH, NR1 --CH, S(O)u --CH or O--CH; X3 is CR5 R5 ', NR5, S(O)u or O; R2 is --OR', --NR'R", --NR'SO2 R'", --NR'OR', --OCR'2 C(O)OR', --OCR'2 OC(O)--R', --OCR'2 C(O)NR'2, CF3 or --COCR'2 R2 '; R3, R4 and R7 are independently H, halo, --OR12, --SR12, --CN, --NR'R12, --NO2, --CF3, CF3 S(O)r --, --CO2 R', --CONR'2, R14 --C0-6 alky-, R14 --C1-6 oxoalkyl-, R14 --C2-6 alkenyl-, R14 --C2-6 alkynyl-, R14 --C0-6 alkyloxy-, R14 --C0-6 alkylamino- or R14 --C0-6 alkyl--S(O)r --; R6 is W--(CR'2)q --Z--(CR'R10)--U--(CR'2)s --V-- or W'--(CR'2)q --U--(CR'2)s -- U and V are absent or CO, CR'2, C(=CR152), S(O)n, O, NR15, CR15 'OR15, CR'(OR")CR'2, CR'2 CR'(OR") C(O)CR'2, CR152 C(O), CONR15, NR15 CO, OC(O), C(O)O, C(S)O, OC(S), C(S)NR15, NR15 C(S), SO2 NR15, NR15 SO2, N=N, NR15 NR15, NR15 CR152, NR15 CR152, CR152 O, OCR152, C$(m)ZC, CR15 =CR15, Het, or Ar, provided that U and V are not simultaneously absent, and W and W' are a nitrogen-containing substituent, and integrin receptor antagonists.
Structural and electrochemical studies of some cobalt (III) complexes of 2-aminomethylbenzimidazole and 2-(N-methylaminomethyl) benzimidazole
Cardwell, Terence J.,Edwards, Alison J.,Hartshorn, Richard M.,Holmes, Rodney J.,McFadyen, W. David
, p. 1009 - 1015 (2007/10/03)
A number of mixed-ligand cobalt(III) complexes containing either the ligand 2-aminomethylbenzimidazole (ambi) or its N-methyl derivative, namely 2-(N-methylaminomethyl)benzimidazole (mambi), have been prepared in relatively low yield; in particular, the complexes [Co(ambi)(acac)2] Cl, [Co(ambi)(Clacac)2] Cl, K [Co(ambi)(ox)2], [Co(ambi)2(acac)] (ClO4)2, [Co(mambi)(acac)2] Cl and [Co(mambi)(Clacac)2] Cl (acac = acetylacetonate, Clacac = 3-chloroacetylacetonate, ox = oxalate). The reduction potentials of these complexes have been measured in order to assess whether molecules of this type could be potential redox-activated hypoxic cell selective anticancer agents. The complex [Co(ambi)(acac)2] Cl.4·1H2O was characterized by single-crystal X-ray crystallography: a 19.425(1), b 17.734(1), c 15.979(1) A, β 117.52(1)°, monoclinic, space group C2/c (No. 15).
